Antiretroviral News and Research

RSS

UNMC's ART injectables can successfully treat HIV infection

This has been a good week for breakthroughs in HIV/AIDS. Earlier this week, the Food and Drug Administration approved a daily pill, Truvada, which reduces the risk of HIV infection. Today, a University of Nebraska Medical Center research team's progress toward developing weekly or twice-monthly injectable antiretroviral therapy (ART) nanomedicines for patients with human immunodeficiency virus (HIV) infection will be highlighted as the cover story in the Journal of Infectious Diseases.

19 Jul 2012

Bryologs more potent than prostratin in treating HIV

Thanks to antiretrovirals, an AIDS diagnosis hasn't been a death sentence for nearly two decades. But highly active antiretroviral therapy, or HAART, is also not a cure.

19 Jul 2012

NPR reports on Brazilian clinical trial of Truvada as prevention strategy

NPR's "Shots" blog reports on one of the drug trials considered by the FDA in its approval of the antiretroviral drug Truvada for pre-exposure prophylaxis (PrEP) to prevent HIV among people at risk of contracting the virus, which "was done at the Oswaldo Cruz Foundation Research Institute, also known as Fiocruz, in Rio de Janeiro."

19 Jul 2012

Clinical trial to evaluate maraviroc-based PrEP regimens for HIV prevention

Scientists are launching the first clinical trial to test whether drug regimens containing maraviroc, a medication currently approved to treat HIV infection, are also safe and tolerable when taken once daily by HIV-uninfected individuals at increased risk for acquiring HIV infection. The eventual goal is to see if the drug regimens can reduce the risk of infection.

19 Jul 2012

Truvada gains FDA approval as HIV preventive

The daily pill is the first aimed at reducing the risk of contracting HIV in healthy people who are at high risk of contracting AIDS. It will have a boxed warning that it should be used only by people whose HIV-negative status is confirmed prior to prescription and at least every three months after.

18 Jul 2012

Advocates, policy experts respond to FDA approval of Truvada for HIV prevention

Though the FDA's Monday approval of the antiretroviral drug Truvada for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among people at risk of contracting the virus "was hailed by many as an important step in the fight against AIDS, concerns that people will incorrectly use the drug -- potentially spurring drug resistance -- led others to blast the agency for not laying down tougher rules," the Wall Street Journal's "Health Blog" writes.

18 Jul 2012

FDA approves Truvada as HIV prevention strategy for high-risk, uninfected individuals

The FDA on Monday announced the approval of the first drug for pre-exposure prophylaxis (PrEP) to prevent HIV among people at risk of contracting the virus, "which some are calling a landmark in the fight against AIDS," ABC News reports.

18 Jul 2012

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truto reduce the risk of sexually-acquired HIV infection in adults at high risk.

17 Jul 2012

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine and tenofovir disoproxil fumarate), in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.

17 Jul 2012

Once-daily single-tablet HIV therapy developed

A single tablet containing four antiviral agents may be an effective initial once-daily therapy for adults infected with HIV, shows phase III clinical research.

16 Jul 2012

Trade agreements could harm access to antiretroviral drugs in Asia, Pacific, experts and activists warn

"Pressure on developing countries to adopt clauses affecting intellectual property rights could limit access to generic antiretroviral (ARV) drugs in Asia and the Pacific, experts and activists warn," PlusNews reports.

14 Jul 2012

Research roundup: Medication adherence, performance at community health centers

For people diagnosed with depression, it's important that they adhere to their medication regimen so that they avoid recurrent episodes. But because of Medicare's Part D coverage gap, financially burdened seniors might not take their prescriptions as recommended. This study looked at Medicare beneficiaries diagnosed with depression in 2007.

14 Jul 2012

Studies show success, highlight challenges of PrEP strategy

The results of three clinical trials published on Wednesday in the New England Journal of Medicine show that the antiretroviral drug Truvada, a combination of tenofovir and emtracitabine, can be "highly effective at preventing infection in HIV-free individuals -- as long as those individuals take the drug every day as prescribed," CNN's "The Chart" reports (7/11).

13 Jul 2012

PLoS Medicine papers examine HIV treatment as prevention

Early treatment with antiretroviral medication can significantly reduce the risk of HIV transmission to an uninfected sexual partner, "but many logistical hurdles stand in the way of making this strategy feasible, affordable and effective, according to experts writing in Tuesday's edition of the journal PLoS Medicine," the Los Angeles Times reports.

12 Jul 2012

Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1

Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1.

12 Jul 2012

WHO working on consolidated HIV treatment guidelines

The WHO "says comprehensive HIV treatment strategies are needed in developing countries to overcome stigma and discrimination," because "often those in need of HIV treatment and prevention are unable to receive the services because of their social status," VOA News reports.

11 Jul 2012

HIV infection risk reduced by same drugs that treat HIV

People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.

11 Jul 2012

HIV and AIDS treatment: An interview with Charles Flexner, MD

The best estimates at the moment reckon that there are about 25 million people infected with HIV. Most of those are in resource-limited settings, including sub-Saharan Africa, South East Asia and India.

11 Jul 2012

HIV drug coverage in sub-Saharan Africa continues to improve but not sustainable, UNAIDS' Sidibe says

At the end of 2011, 6.2 million people in sub-Saharan Africa were taking antiretroviral drugs, about 56 percent of the people in need in the region, UNAIDS Executive Director Michel Sidibe noted in an interview last week, saying, "Ten years ago, nobody would have imagined that such a result would be possible," Agence France-Presse reports. "Sidibe -- visiting Paris ahead of the July 22-27 International AIDS Conference in Washington -- said he was worried that African countries remained so dependent on foreign help," the news service states.

10 Jul 2012

Research roundup: Crowded emergency departments, expensive HIV drugs, high deductible insurance plans

Skin In The Game: How Consumer-Directed Plans Affect The Cost And Use Of Health Care -- Consumer-directed health plans, which feature lower premiums and higher deductibles than traditional plans, are designed to reduce costs by discouraging unnecessary care. This brief describes a study of more than 800,000 households that switched from a traditional employer-based plan to a consumer-based plan.

7 Jul 2012